Imara attempts to spin weak data into an 'encouraging' result — but investors aren't having it

Imara unveiled data from two subgroups of a Phase IIa trial for its lead compound Wednesday, aiming to conjure up a positive light despite challenges tied to the Covid-19 pandemic. But investors weren’t buying it and sent the company’s shares into a tailspin.